scholarly journals Long-term efficacy of megestrol acetate and tamoxifen in a recurrent adult granulosa cell tumor of the ovary

2021 ◽  
pp. 100770
Author(s):  
Ashley S. Moon ◽  
Oliver Dorigo
2015 ◽  
Vol 37 (8) ◽  
pp. e486-e489 ◽  
Author(s):  
Martin Benesch ◽  
Herwig Lackner ◽  
Alexander Pilhatsch ◽  
Barbara Gürtl-Lackner ◽  
Wolfgang Schwinger ◽  
...  

2012 ◽  
Vol 38 (12) ◽  
pp. 1379-1384 ◽  
Author(s):  
Tomohito Tanaka ◽  
Takashi Kato ◽  
Masahide Ohmichi

2013 ◽  
Author(s):  
Cigdem Bahadir ◽  
Aysegul Atmaca ◽  
Hulusi Atmaca ◽  
Ramis Colak

2017 ◽  
Vol 2 (16) ◽  
pp. 48
Author(s):  
D. Oprescu ◽  
C. Herghelegiu ◽  
A. Moldoveanu

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Itsuki Koganezawa ◽  
Koichi Tomita ◽  
Masashi Nakagawa ◽  
Yosuke Ozawa ◽  
Toshimichi Kobayashi ◽  
...  

2016 ◽  
Author(s):  
Geetanjali Tuteja ◽  
S. Unmesh ◽  
S. Shree ◽  
S. Rudra ◽  

The differential diagnosis for precocious puberty in a young female includes peripheral causes. This case report documents a rare cause of isosexual precocious puberty, a juvenile granulosa cell tumour of the ovary–and a brief literature review. A one year-old baby girl presented with mass abdomen, vaginal discharge and rapid onset of pubertal development. She underwent an exploratory laparotomy for tumour resection. Pathology reported a juvenile granulosa cell tumour of the ovary. Early stage granulosa cell tumor surgically treated has good prognosis. Adjuvant chemotherapy is not indicated in this setting.


2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Christian Secchi ◽  
Paola Benaglio ◽  
Francesca Mulas ◽  
Martina Belli ◽  
Dwayne Stupack ◽  
...  

Abstract Background Adult granulosa cell tumor (aGCT) is a rare type of stromal cell malignant cancer of the ovary characterized by elevated estrogen levels. aGCTs ubiquitously harbor a somatic mutation in FOXL2 gene, Cys134Trp (c.402C < G); however, the general molecular effect of this mutation and its putative pathogenic role in aGCT tumorigenesis is not completely understood. We previously studied the role of FOXL2C134W, its partner SMAD3 and its antagonist FOXO1 in cellular models of aGCT. Methods In this work, seeking more comprehensive profiling of FOXL2C134W transcriptomic effects, we performed an RNA-seq analysis comparing the effect of FOXL2WT/SMAD3 and FOXL2C134W/SMAD3 overexpression in an established human GC line (HGrC1), which is not luteinized, and bears normal alleles of FOXL2. Results Our data shows that FOXL2C134W/SMAD3 overexpression alters the expression of 717 genes. These genes include known and novel FOXL2 targets (TGFB2, SMARCA4, HSPG2, MKI67, NFKBIA) and are enriched for neoplastic pathways (Proteoglycans in Cancer, Chromatin remodeling, Apoptosis, Tissue Morphogenesis, Tyrosine Kinase Receptors). We additionally expressed the FOXL2 antagonistic Forkhead protein, FOXO1. Surprisingly, overexpression of FOXO1 mitigated 40% of the altered genome-wide effects specifically related to FOXL2C134W, suggesting it can be a new target for aGCT treatment. Conclusions Our transcriptomic data provide novel insights into potential genes (FOXO1 regulated) that could be used as biomarkers of efficacy in aGCT patients.


Author(s):  
Jessica A Pilsworth ◽  
Dawn R Cochrane ◽  
Samantha J Neilson ◽  
Bahar H Moussavi ◽  
Daniel Lai ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document